Merestinib
CAS No. 1206799-15-6
Merestinib ( LY2801653 )
Catalog No. M17192 CAS No. 1206799-15-6
LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.
Purity : 95%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 58 | In Stock |
|
5MG | 96 | In Stock |
|
10MG | 132 | In Stock |
|
25MG | 240 | In Stock |
|
50MG | 402 | In Stock |
|
100MG | 573 | In Stock |
|
500MG | 1197 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMerestinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.
-
DescriptionLY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. LY2801653 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing the constitutively activated c-Met protein.
-
SynonymsLY2801653
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetKinesin
-
RecptorMet
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1206799-15-6
-
Formula Weight552.54
-
Molecular FormulaC30H22F2N6O3
-
Purity95%
-
SolubilityDMSO : ≥ 32 mg/mL. 57.92 mM
-
SMILESc1(=O)c(ccc(n1c1ccc(cc1)F)C)C(=O)Nc1cc(c(cc1)Oc1cc2cnn(c2cc1c1cn[nH]c1)C)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yan SB, Peek VL, Ajamie R, et al. Invest New Drugs. 2012 Dec 29. [Epub ahead of print]
molnova catalog
related products
-
TUG-891
TUG-891 is a G protein-coupled receptor (GPCR) expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids.
-
Kif15-IN-1
Kif15-IN-1 is a potent, selective inhibitor of KIF15 motility, can act synergistically with Eg5 inhibitors to impair cancer cell proliferation.
-
Paprotrain
Paprotrain inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM.